130 related articles for article (PubMed ID: 1397246)
1. Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
Palumbo A; Boccadoro M; Garino LA; Gallone G; Frieri R; Pileri A
Eur J Haematol; 1992 Aug; 49(2):93-7. PubMed ID: 1397246
[TBL] [Abstract][Full Text] [Related]
2. Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in relapsed myeloma.
Palumbo A; Boccadoro M; Garino LA; Gallone G; Frieri R; Pileri A
Acta Haematol; 1993; 90(2):71-6. PubMed ID: 8285021
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
4. Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy.
Palumbo AP; Garino AL; Frieri R; Gallone G; Boccadoro M; Pileri A
Haematologica; 1990; 75(6):576-8. PubMed ID: 2098302
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
6. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
8. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
Salmon SE; Crowley JJ; Balcerzak SP; Roach RW; Taylor SA; Rivkin SE; Samlowski W
J Clin Oncol; 1998 Mar; 16(3):890-6. PubMed ID: 9508170
[TBL] [Abstract][Full Text] [Related]
9. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Dimopoulos MA; Weber D; Delasalle KB; Alexanian R
Cancer; 1993 Nov; 72(9):2589-92. PubMed ID: 8402480
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].
Adam Z; Krejcí M; Bacovský J; Hejlová N; Kuca B; Svojgrová M; Franková H; Gumulec J; Janca J; Veprek K; Januska B; Lehanka F; Rezek Z; Praskac P; Cahová S; Vránová M; Papajík T; Králová E; Novotná J; Scudla V; Koza V; Drbal J; Faber E; Mareschová I; Hájek R
Vnitr Lek; 1998 Jul; 44(7):400-8. PubMed ID: 9748876
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interferon-alpha 2b and high dose methyl prednisolone in relapsed and resistant multiple myeloma.
Ganjoo RK; Johnson PW; Evans ML; Williams A; Rohatiner AZ; Lister TA; Malpas JS
Hematol Oncol; 1993; 11(4):179-86. PubMed ID: 8144132
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma.
Abrahamson GM; Bird JM; Newland AC; Gaminara E; Giles C; Joyner M; Kelsey SM; Lewis D; McCarthy DM; Roques AW; Tew CJ; Treacy M; van de Pette J; Samson D
Br J Haematol; 1996 Sep; 94(4):659-64. PubMed ID: 8826889
[TBL] [Abstract][Full Text] [Related]
15. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
Westin J; Cortelezzi A; Hjorth M; Rödjer S; Turesson I; Zador G
Eur J Cancer; 1991; 27 Suppl 4():S45-8. PubMed ID: 1799477
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
Westin J; Rödjer S; Turesson I; Cortelezzi A; Hjorth M; Zador G
Br J Haematol; 1995 Mar; 89(3):561-8. PubMed ID: 7734355
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
19. Rapid response to recombinant interferon alpha 2B and high-dose prednisone in multiple drug-resistant multiple myeloma.
Wahlin A; Holm J
Eur J Haematol; 1989 Oct; 43(4):352-4. PubMed ID: 2583262
[No Abstract] [Full Text] [Related]
20. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
Westin J
Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]